You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IDH1/2

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent IDH1/2 Mutated Glioma Trial in Paris (Azacitidine)

Recruiting
  • Recurrent IDH1/2 Mutated Glioma
  • Paris, France
    Pitie Salpetriere Hospital
Aug 29, 2022

Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma Trial in Boston (Niraparib, Resection/Treatment with Niraparib)

Recruiting
  • Low-grade Glioma
  • +4 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 19, 2022

Brain Tumor, Cancer Trial run by the National Cancer Institute (NCI) (Zotiraciclib)

Not yet recruiting
  • Brain Tumor
  • Cancer
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic Trial (Ivosidenib)

Not yet recruiting
  • Cholangiocarcinoma Non-resectable
  • Cholangiocarcinoma Metastatic
  • (no location specified)
Oct 10, 2023

IDH1-mutant Cholangiocarcinoma Trial (Ivosidenib, Recommended Combination Dose (RCD) of ivosidenib, Nivolumab)

Not yet recruiting
  • IDH1-mutant Cholangiocarcinoma
  • (no location specified)
Jun 29, 2023

Acute Myeloid Leukemia (AML) Trial in United States (Gilteritinib, Ivosidenib, Enasidenib)

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • Basking Ridge, New Jersey
  • +6 more
Mar 3, 2023

Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer Trial in Edmonton, Toronto (Enasidenib, Venetoclax)

Active, not recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Edmonton, Alberta, Canada
  • +1 more
Jan 31, 2023

Glioma Trial in Melbourne (Biopsy, Part A: AB-218, Surgery (maximal resection))

Recruiting
  • Glioma
  • Biopsy
  • +3 more
  • Melbourne, Victoria, Australia
    Royal Melbourne Hospital
Oct 11, 2022

Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme Trial in Cleveland (Eflornithine (Dose Level 1), Eflornithine

Recruiting
  • Glioblastoma, IDH-wildtype
  • +4 more
  • Eflornithine (Dose Level 1)
  • +3 more
  • Cleveland, Ohio
    The Cleveland Clinic
May 19, 2023

Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult Trial (NEO212 Oral Capsule, Ipilimumab,

Not yet recruiting
  • Diffuse Astrocytoma, IDH-Mutant
  • +20 more
  • NEO212 Oral Capsule
  • +8 more
  • (no location specified)
Sep 18, 2023

Astrocytoma, Grade IV, Glioblastoma, Giant Cell Glioblastoma Trial in United States (CYNK-001 systemic and Intra cavity

Recruiting
  • Astrocytoma, Grade IV
  • +3 more
  • CYNK-001 systemic and Intra cavity administration
  • Duarte, California
  • +5 more
Jan 20, 2023

Glioma Trial (AB-218)

Not yet recruiting
  • Glioma
  • (no location specified)
Mar 29, 2022

Glioma, Recurrence, Disease Attributes Trial (Vorasidenib)

Available
  • Glioma
  • +10 more
  • (no location specified)
Oct 19, 2022

Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma Trial in Houston (other,

Recruiting
  • Anaplastic Astrocytoma, IDH-Wildtype
  • +8 more
  • Quality-of-Life Assessment
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 8, 2022

Glioma, IDH Mutation, Astrocytoma Trial in Philadelphia (Retifanlimab, All-trans retinoic acid)

Not yet recruiting
  • Glioma
  • +3 more
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Jul 22, 2022

Glioma Trial in United States (AG881)

Active, not recruiting
  • Glioma
  • Los Angeles, California
  • +8 more
May 16, 2022

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Cobimetinib, Enasidenib Mesylate)

Not yet recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Duarte, California
    City of Hope Medical Center
Jun 28, 2022

IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation Trial in Chicago (Ivosidenib, Enasidenib, Fedratinib)

Recruiting
  • IDH Mutation
  • +4 more
  • Chicago, Illinois
    University of Chicago Medical Center
Nov 12, 2021

Non Invasive IDentification of Gliomas With IDH1 Mutation

Completed
  • Non Invasive Diagnosis of Glioma
    • Paris, Sélectionner..., France
      GH Pitié-Salpêtrière, 47 Bd de l'Hopital,
    Aug 25, 2021

    Glioblastoma, Glioblastoma Multiforme, Glioma Trial in Phoenix, San Francisco (Niraparib, Radiation therapy)

    Recruiting
    • Glioblastoma
    • +5 more
    • Phoenix, Arizona
    • +1 more
    Dec 7, 2021

    Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Decitabine and

    Recruiting
    • Acute Myeloid Leukemia
    • +2 more
    • Decitabine and Cedazuridine
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jun 29, 2022

    Cholangiocarcinoma With IDH1 Mutation, Solid Tumors With IDH1 Mutation Trial in Beijing (AB-218 capsule)

    Not yet recruiting
    • Cholangiocarcinoma With IDH1 Mutation
    • Solid Tumors With IDH1 Mutation
    • AB-218 capsule
    • Beijing, Beijing, China
      Peking Union Medical College Hospital, Chinese Academy of Medica
    Apr 2, 2023

    AML, Adult Trial in Italy (IDH mutation test performed at diagnosis or relapse until January 31st, 2019.)

    Completed
    • AML, Adult
    • IDH mutation test performed at diagnosis or relapse until January 31st, 2019.
    • Alessandria, Italy
    • +23 more
    Dec 31, 2021

    IDH Family Wildtype, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma Trial in Houston (Laser Interstitial Thermal

    Terminated
    Has Results
    • IDH Family Wildtype
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 14, 2022

    Recurrent Acute Myeloid Leukemia Trial in United States (Enasidenib Mesylate, Liposome-encapsulated Daunorubicin-Cytarabine)

    Suspended
    • Recurrent Acute Myeloid Leukemia
    • Enasidenib Mesylate
    • Liposome-encapsulated Daunorubicin-Cytarabine
    • Los Angeles, California
    • +3 more
    Sep 27, 2022